Drugs / PF00562271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00666926 | Dec 2005 → Apr 2009 | head and neck neoplasm, pancreatic neoplasm, prostate neoplasm | Verastem, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-00562271 | “focal adhesion kinase (FAK) inhibitor PF-00562271” NCT00666926 ↗ |
| Known as | PF 00562271-26 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084546 ↗ |
| Known as | Pf-562271 besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084546 ↗ |
| Action | Inhibit | “focal adhesion kinase (FAK) inhibitor PF-00562271” NCT00666926 ↗1“Focal adhesion kinase 1 inhibitor” CHEMBL1084546 ↗ |
| Modality | Small molecule | — CHEMBL1084546 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL1084546 ↗ |